生血康对特发性血小板减少性紫癜患者骨髓巨核细胞的影响

目的：观察生血康治疗特发性血小板减少性紫癜（ITP）患者骨髓巨核细胞的变化．方法：治疗组30例，采用生血康（蒙药制剂）3g，每日3次口服，对照组30例，强的松1mg／（ks．d），每日1次顿服（或每日分3次口服）．两组均以6周为一个疗程，6周后强的松逐减量．并观察骨髓象的变化．结果：治疗组治疗后原、幼巨核和颗粒型巨核细胞明显减少，产板型巨核细胞明显增多，与对照组比较具有显著性差异（P〈0．05）．结论：生血康具有促进骨髓巨核细胞的成熟，使原、幼巨核和颗粒型巨核细胞减少，产板型巨核细胞增多致使升高血小板之功能。

Effect of Shengxuekang on Megakaryocyte of Patient with ITP

Objective:To observe megakaryocyte' s changes of patients with idiopathic thrombocytopenic purpura ( ITP) treated with Shengxuekang ( SXK, Mongolian medicine) . Methods: Treatment group had 30 patients. We treated the patients with SXK, 3g three times a day. Control group had 30 patients. We treated the patients with prednisone, 1mg/kg/d,one time a day. The treatment course of both groups lasted six weeks. We gradually reduced the dosage of prednisone six weeks later. Results: In treatment group, megakaryoblast, promegakarypcyte and granular megakaryocyte decreased. At the same time plateelet - producing megakaryocyte increased. The difference between the two groups is significant (p<0.05). Conclusion: It shows SXK has the function that increases platelet through promoting maturity of megakaryocyte, decreases the amount of megakaryoblast and promegakaryocyte and increases the amount of platelet - producing megakaryocyte.